Sunvozertinib

Drug profile

Key facts

Sunvozertinib is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2025. DrugCentral lists 2 molecular targets, including EGFR and BTK. Recorded indications include Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

• Approval status: onp (first approved 2025 by the FDA).
• Molecular targets: EGFR and BTK (2 listed in DrugCentral).
• Indications: Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
• Molecular formula: C29H35ClFN7O3; molecular weight 584.10 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
Epidermal growth factor receptor	EGFR	inhibitor	IC50 8.62
Tyrosine-protein kinase BTK	BTK	inhibitor	IC50 8.54

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2025-07-02	FDA	—	Dizal Pharmaceutical

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Sunvozertinib is on its molecule page.

• Molecular formula: C₂₉H₃₅ClFN₇O₃
• Molecular weight: 584.10 g/mol
• CAS number: —
• InChIKey: BTMKEDDEMKKSEF-QGZVFWFLSA-N
• PubChem CID: 139377809

CC(C)(C1=CC(=C(C=C1NC2=NC(=NC=C2)NC3=C(C=C(C(=C3)NC(=O)C=C)N4CC[C@H](C4)N(C)C)OC)Cl)F)O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sunvozertinib used for?

DrugCentral lists the following indications for Sunvozertinib: Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

How does Sunvozertinib work?

Its molecular targets in DrugCentral include EGFR (inhibitor) and BTK (inhibitor).

When was Sunvozertinib first approved?

Sunvozertinib was first approved by the FDA in 2025.

What is the chemical formula of Sunvozertinib?

Sunvozertinib has the molecular formula C29H35ClFN7O3 and a molecular weight of 584.10 g/mol.

Sources

• DrugCentral drug card 5778 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL5314564 — compound record and bioactivity
• PubChem CID 139377809 — chemical identifiers
• FDA UNII L1Q2K5JYO8 — substance identity
• DailyMed: FDA labels for Sunvozertinib — current prescribing information (label search)
• UniProt P00533 (EGFR) — target protein
• UniProt Q06187 (BTK) — target protein

How this page is built: methodology · editorial policy & corrections.